36 results on '"Henry, N. Lynn"'
Search Results
2. Correction to: Impact of the Integrative Oncology Scholars Program on Oncology Providers’ Key Knowledge of Dietary Supplements and Antioxidants for Providing Evidence-based Oncology Care
3. Impact of the Integrative Oncology Scholars Program on Oncology Providers’ Key Knowledge of Dietary Supplements and Antioxidants for Providing Evidence-based Oncology Care
4. Breast cancer survivorship and sexual dysfunction: a population-based cohort study
5. Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
6. Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data
7. Factors influencing scalp cooling discussions and use at a large academic institution: a single-center retrospective review
8. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms
9. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel
10. Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
11. Cancer-Related Cognitive Impairment or “Chemobrain:” Emerging Assessments, Treatments, and Targets for Intervention
12. Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability
13. Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer
14. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
15. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy
16. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study
17. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion
18. Factors influencing the use of extended adjuvant endocrine therapy
19. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)
20. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy
21. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients
22. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors
23. Extended Endocrine Therapy: Is 5 Years Enough?
24. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer
25. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
26. Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay
27. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
28. Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence
29. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover
30. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer
31. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
32. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
33. Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors
34. One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy
35. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
36. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.